News & Analysis on Clinical Trial Services & Contract Research And Development
The Danish company becomes the latest large pharma company to invest in NLRP3 assets, with these types of treatments holding the potential to treat a variety of diseases linked to inflammation.
The company states that with the expansion of its digital services, its digital supply chain operations platform is the first end-to-end solution of its kind on the market.
OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.